Centessa Pharmaceuticals is focused on developing transformative treatment options for patients with various disorders, including sleep-wake, neurological, neurodegenerative, and psychiatric disorders through programs like the Orexin Receptor 2 Agonist Program and LockBody® Technology Platform.

Centessa Pharmaceuticals

Centessa Pharmaceuticals | 6,972 followers on LinkedIn. A new kind of pharmaceutical company delivering asset centricity at scale. | Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with a Research &amp; Development innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&amp;D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development.

Kristen K. Sheppard, Esq.

Head of Biology, Orexin Program, Centessa Pharmaceuticals

Sarah (Sally) Wurts Black

Financial Reporting, Compliance and Fun!

Satish Girirajan

Chief Financial Officer at Centessa Pharmaceuticals

John Crowley, C.P.A.

Today, Centessa announced Q3FY24 financial results and provided a business update highlighting our growing orexin agonist pipeline. Read the full release here: https://lnkd.in/ePc9TYKj

Today, Centessa announced additional interim data from the ongoing Phase 1 study of its novel orexin agonist, supporting its best-in-class potential for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Based on the strength of these data, we have initiated a Phase 2a study in patients with NT1, NT2 and IH and expect data in all three indications in 2025. Read the full release here: https://lnkd.in/ePc9TYKj

Great weekend spent connecting with individuals living with sleep disorders at the Hypersomnia Foundation #BeyondSleepySatellite event in Atlanta, GA. Photo includes Centessa’s orexin agonist program team members Deborah Hartman, PhD and Suman Machinani, MD, together with Claire Wylds-Wright (right) and Lindsay Jesteadt, Ph.D (left), the CEO and COO respectively, of the Hypersomnia Foundation .

Centessa is a proud sponsor of the Illuminate Hypersomnia initiative. As an advocate for sleep-wake disorders, we’re not only helping to shine a light on the challenges faced by those living with idiopathic hypersomnia (IH), but also working to develop a potentially transformative treatment to address their needs. Learn more about Centessa's orexin agonist program: https://lnkd.in/etK4De5m

Today, Centessa shared new preclinical data from non-human primate (NHP) studies of ORX142, an investigational, novel, orexin receptor 2 (OX2R) agonist being advanced for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative and psychiatric disorders, at European Sleep Research Society - Sleep Europe 2024. We are focused on rapidly moving ORX142, the second drug candidate from our growing pipeline of OX2R agonists, through IND-enabling studies. #SleepEurope Read full release here: https://lnkd.in/emCdGfQF

Thank you Tatiana Corbitt and Katelynn O'Connell for joining our recent Town Hall! In recognition of World Narcolepsy Day, we were honored to host two inspiring patient advocates who shared their personal journeys with narcolepsy. We share their passion to drive awareness for both narcolepsy and other sleep-wake disorders and are committed to helping make a difference. #PatientAdvocacy #WorldNarcolepsyDay #CNTAOX2R

September 22nd is World Narcolepsy Day! Join Centessa in raising awareness and understanding about narcolepsy—a chronic sleep disorder that affects millions worldwide. Narcolepsy isn’t just about feeling sleepy; it involves sudden and uncontrollable episodes of falling asleep, cataplexy (sudden loss of muscle tone), and other challenging symptoms. Narcolepsy and other sleep-wake disorders impact daily life. Help shine a light on the experiences of those living with narcolepsy by recognizing World Narcolepsy Day. Together, we can make a difference! Learn more about how the Centessa team is advancing a pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists for the treatment of narcolepsy and idiopathic hypersomnia, as well as excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders. https://lnkd.in/etK4De5m #WorldNarcolepsyDay #NarcolepsyAwareness

Based on the positive interim data from the ongoing Phase 1 study reported today, Centessa plans to advance ORX750 into Phase 2 studies in patients with narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, beginning in the fourth quarter of 2024. Centessa plans to further leverage these data to expedite the progression of its multi-asset orexin franchise to potentially treat excessive daytime sleepiness across multiple disorders. Read more here: https://lnkd.in/eyW74rkC

Today, Centessa announced positive interim data from the ongoing Phase 1 study of ORX750, a potential best-in-class oral OX2R agonist for the treatment of sleep-wake disorders. At a 2.5 mg once-daily dose, ORX750 was shown to restore normative wakefulness in acutely sleep-deprived healthy volunteers and, as of the data cutoff date, has demonstrated a favorable safety and tolerability profile. To learn more, click here: https://lnkd.in/eyW74rkC

CENT

COM:CENTESSA

Centessa Pharmaceuticals